8-K: bioAffinity Technologies Announces Warrant Inducement for $1.4 Million Gross Proceeds

bioAffinity Technologies secures $1.4 million through a warrant inducement agreement, issuing new warrants to incentivize the exercise of existing ones.

Summary

• bioAffinity Technologies, Inc. entered into a warrant inducement agreement with certain holders of the company's warrants to purchase common stock.
• Holders agreed to exercise October Warrants for up to 1,302,082 shares and August Warrants for up to 1,136,391 shares at a reduced exercise price of $0.58 per share.
• The company received approximately $1.4 million in gross proceeds before deducting fees and expenses.
• In consideration, the company issued new unregistered Common Stock Purchase Warrants to purchase up to 2,926,166 shares of Common Stock (120% of the number of Existing Warrant Shares issued upon exercise of the Existing Warrants).
• The new warrants have an exercise price of $0.85 per share and are exercisable after stockholder approval, expiring five years from the approval date.
• WallachBeth Capital, LLC acted as the financial advisor and received a cash fee of 8.0% of the gross proceeds and warrants to purchase 87,785 shares of Common Stock.
• The company intends to use the net proceeds for working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: The announcement is generally positive as it secures additional funding for the company. However, the potential dilution from new warrants and the fees paid to the financial advisor temper the overall sentiment.

Positives

• The warrant inducement generated approximately $1.4 million in gross proceeds for the company.
• The company secured additional capital for working capital and general corporate purposes.
• The exercise of existing warrants simplifies the company's capital structure.
• The financial advisor has a right of first refusal for future offerings, potentially streamlining future capital raises.
• CyPath Lung is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer.

Negatives

• The company incurred fees and expenses related to the warrant inducement, including an 8.0% cash fee to the financial advisor.
• The issuance of new warrants could dilute existing shareholders if exercised.
• The company needs to obtain stockholder approval for the new warrants to be exercisable.
• The financial advisor received warrants equal to approximately 3.0% of the number of New Warrant Shares issued in the offering.

Risks

• The company's ability to have the Resale Registration Statement declared effective by the SEC.
• The company's ability to keep the Resale Registration Statement effective at all times until the Holders no longer own any New Warrants or New Warrant Shares.
• The company's ability to obtain stockholder approval for the new warrants.
• The company's ability to close the offering.
• The company's ability to use the net proceeds from these transactions for working capital and other general corporate purposes.

Future Outlook

The company expects to use the net proceeds from these transactions for working capital and other general corporate purposes and will file a registration statement to register the resale of the New Warrant Shares as soon as practicable.

Industry Context

Warrant inducement agreements are a common mechanism for companies to raise capital and incentivize warrant holders to exercise their options, providing immediate cash flow in exchange for potentially dilutive future equity issuances.

Comparison to Industry Standards

• The 8% cash fee to the financial advisor is within the typical range for placement agent fees in similar warrant inducement transactions, although the specific percentage can vary based on the size and complexity of the deal.
• The issuance of new warrants representing 120% of the exercised shares is a relatively standard incentive to encourage warrant holders to participate in the inducement.
• The $0.85 exercise price for the new warrants reflects the company's current stock price and market conditions, aiming to strike a balance between attracting investors and minimizing dilution.

Stakeholder Impact

• Shareholders may experience dilution if the new warrants are exercised.
• The company's financial position is strengthened by the additional capital.
• The company can continue to develop and market CyPath Lung.

Next Steps

• The company needs to obtain stockholder approval for the new warrants.
• The company will file a resale registration statement for the new warrant shares.
• The company will use the proceeds for working capital and general corporate purposes.

Key Dates